*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][4]. Group 1: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Inovio regarding claims of potential securities fraud and is encouraging them to contact the firm for further information [1].